These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 8294904)

  • 1. Lesions of mouse striatum induced by 6-hydroxydopamine differentially alter the density, rate of synthesis, and level of gene expression of D1 and D2 dopamine receptors.
    Qin ZH; Chen JF; Weiss B
    J Neurochem; 1994 Feb; 62(2):411-20. PubMed ID: 8294904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cholinergic lesions of mouse striatum induced by AF64A alter D2 dopaminergic behavior and reduce D2 dopamine receptors and D2 dopamine receptor mRNA.
    Zhou LW; Zhang SP; Connell TA; Weiss B
    Neurochem Int; 1993 Mar; 22(3):301-11. PubMed ID: 8443571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oligodeoxynucleotide antisense to the D1 dopamine receptor mRNA inhibits D1 dopamine receptor-mediated behaviors in normal mice and in mice lesioned with 6-hydroxydopamine.
    Zhang SP; Zhou LW; Weiss B
    J Pharmacol Exp Ther; 1994 Dec; 271(3):1462-70. PubMed ID: 7996459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo administration of an oligodeoxynucleotide antisense to the D2 dopamine receptor messenger RNA inhibits D2 dopamine receptor-mediated behavior and the expression of D2 dopamine receptors in mouse striatum.
    Zhou LW; Zhang SP; Qin ZH; Weiss B
    J Pharmacol Exp Ther; 1994 Feb; 268(2):1015-23. PubMed ID: 8113958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 6-hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1- and D2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding.
    Breese GR; Duncan GE; Napier TC; Bondy SC; Iorio LC; Mueller RA
    J Pharmacol Exp Ther; 1987 Jan; 240(1):167-76. PubMed ID: 3100767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic treatment with dopamine receptor antagonists: behavioral and pharmacologic effects on D1 and D2 dopamine receptors.
    Hess EJ; Norman AB; Creese I
    J Neurosci; 1988 Jul; 8(7):2361-70. PubMed ID: 2907912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alterations in the turnover rate of dopamine D1 but not D2 receptors in the adult rat neostriatum after a neonatal dopamine denervation.
    Dewar KM; Paquet M; Reader TA
    Neurochem Int; 1997 Jun; 30(6):613-21. PubMed ID: 9153003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Time dependent changes in DA uptake sites, D1 and D2 receptor binding and mRNA after 6-OHDA lesions of the medial forebrain bundle in the rat brain.
    Narang N; Wamsley JK
    J Chem Neuroanat; 1995 Jul; 9(1):41-53. PubMed ID: 8527037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intrastriatal administration of an oligodeoxynucleotide antisense to the D2 dopamine receptor mRNA inhibits D2 dopamine receptor-mediated behavior and D2 dopamine receptors in normal mice and in mice lesioned with 6-hydroxydopamine.
    Zhou LW; Zhang SP; Weiss B
    Neurochem Int; 1996 Dec; 29(6):583-95. PubMed ID: 9113126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intrastriatal dopamine-rich implants reverse the changes in dopamine D2 receptor densities caused by 6-hydroxydopamine lesion of the nigrostriatal pathway in rats: an autoradiographic study.
    Savasta M; Mennicken F; Chritin M; Abrous DN; Feuerstein C; Le Moal M; Herman JP
    Neuroscience; 1992; 46(3):729-38. PubMed ID: 1532053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Irreversible blockade of D2 dopamine receptors by fluphenazine-N-mustard increases D2 dopamine receptor mRNA and proenkephalin mRNA and decreases D1 dopamine receptor mRNA and mu and delta opioid receptors in rat striatum.
    Chen JF; Aloyo VJ; Qin ZH; Weiss B
    Neurochem Int; 1994 Oct; 25(4):355-66. PubMed ID: 7820070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective unilateral inactivation of striatal D1 and D2 dopamine receptor subtypes by EEDQ: turning behavior elicited by D2 dopamine receptor agonists.
    Giorgi O; Biggio G
    Brain Res; 1990 Nov; 533(1):53-9. PubMed ID: 1982234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antisense oligodeoxynucleotide inhibits D2 dopamine receptor-mediated behavior and D2 messenger RNA.
    Weiss B; Zhou LW; Zhang SP; Qin ZH
    Neuroscience; 1993 Aug; 55(3):607-12. PubMed ID: 8413923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repeated D1 dopamine receptor agonist administration prevents the development of both D1 and D2 striatal receptor supersensitivity following denervation.
    Hu XT; White FJ
    Synapse; 1992 Mar; 10(3):206-16. PubMed ID: 1532677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dopamine receptor alterations correlate with increased GABA levels in adult rat neostriatum: effects of a neonatal 6-hydroxydopamine denervation.
    Molina-Holgado E; Van Gelder NM; Dewar KM; Reader TA
    Neurochem Int; 1995; 27(4-5):443-51. PubMed ID: 8845745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High frequency electro-acupuncture enhances striatum DAT and D1 receptor expression, but decreases D2 receptor level in 6-OHDA lesioned rats.
    Rui G; Guangjian Z; Yong W; Jie F; Yanchao C; Xi J; Fen L
    Behav Brain Res; 2013 Jan; 237():263-9. PubMed ID: 23036843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of neuroleptic activity of 9,10-didehydro-N-methyl-(2-propynyl)-6-methyl-8-aminomethylergoline bimaleinate (LEK-8829) by D1 intrinsic activity in hemi-parkinsonian rats.
    Glavan G; Sket D; Zivin M
    Mol Pharmacol; 2002 Feb; 61(2):360-8. PubMed ID: 11809861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. D1 priming enhances both D1- and D2-mediated rotational behavior and striatal Fos expression in 6-hydroxydopamine lesioned rats.
    Pollack AE; Thomas LI
    Pharmacol Biochem Behav; 2010 Jan; 94(3):346-51. PubMed ID: 19800912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective inactivation of dopamine D1 and D2 receptors in 6-hydroxydopamine-lesioned rats: evidence that the effect of D1 and D2 agonists can be expressed in the absence of the heterologous DA receptor.
    Arnt J; Hyttel J
    Pharmacol Toxicol; 1989 Jan; 64(1):116-9. PubMed ID: 2526946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dopamine receptor blockade increases dopamine D2 receptor and glutamic acid decarboxylase mRNAs in mouse substantia nigra.
    Qin ZH; Weiss B
    Eur J Pharmacol; 1994 Sep; 269(1):25-33. PubMed ID: 7828655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.